At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 235 enrolled
Drug / intervention
BMS-986179 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986179, Nivolumab, and 1 other intervention for Malignant Solid Tumor. Completed, enrolled 235 participants across 24 sites in 7 countries.
Detailed Summary
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Solid Tumor
CountriesAustralia, Canada, France, Germany, Italy, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJun 2016
Primary CompletionOct 2021
TodayJul 2026
First PostedApr 28, 2016
Enrollment StartJun 21, 2016
Primary CompletionOct 12, 2021
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 10.2 years ago
Interventions
BMS-986179biological
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days
rHuPH20biological
Specified dose on specified days